Contineum Therapeutics (CTNM) Competitors $7.26 +0.31 (+4.46%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$7.08 -0.18 (-2.41%) As of 08/14/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTNM vs. SIGA, GYRE, MRVI, ABUS, ZVRA, PROK, DNTH, MGTX, GHRS, and DAWNShould you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Siga Technologies (SIGA), Gyre Therapeutics (GYRE), Maravai LifeSciences (MRVI), Arbutus Biopharma (ABUS), Zevra Therapeutics (ZVRA), ProKidney (PROK), Dianthus Therapeutics (DNTH), MeiraGTx (MGTX), GH Research (GHRS), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical products" industry. Contineum Therapeutics vs. Its Competitors Siga Technologies Gyre Therapeutics Maravai LifeSciences Arbutus Biopharma Zevra Therapeutics ProKidney Dianthus Therapeutics MeiraGTx GH Research Day One Biopharmaceuticals Siga Technologies (NASDAQ:SIGA) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations. Which has better earnings & valuation, SIGA or CTNM? Siga Technologies has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSiga Technologies$138.72M4.43$59.21M$1.137.59Contineum Therapeutics$50M3.76-$42.26M-$2.20-3.30 Does the media refer more to SIGA or CTNM? In the previous week, Contineum Therapeutics had 7 more articles in the media than Siga Technologies. MarketBeat recorded 11 mentions for Contineum Therapeutics and 4 mentions for Siga Technologies. Contineum Therapeutics' average media sentiment score of 0.94 beat Siga Technologies' score of 0.49 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Siga Technologies 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Contineum Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, SIGA or CTNM? Siga Technologies has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Do institutionals & insiders have more ownership in SIGA or CTNM? 55.4% of Siga Technologies shares are owned by institutional investors. 2.0% of Siga Technologies shares are owned by company insiders. Comparatively, 11.3% of Contineum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is SIGA or CTNM more profitable? Siga Technologies has a net margin of 45.73% compared to Contineum Therapeutics' net margin of 0.00%. Siga Technologies' return on equity of 40.52% beat Contineum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Siga Technologies45.73% 40.52% 35.62% Contineum Therapeutics N/A -29.75%-28.08% Do analysts rate SIGA or CTNM? Contineum Therapeutics has a consensus target price of $22.50, indicating a potential upside of 209.92%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Contineum Therapeutics is more favorable than Siga Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 SummarySiga Technologies beats Contineum Therapeutics on 9 of the 17 factors compared between the two stocks. Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTNM vs. The Competition Export to ExcelMetricContineum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$179.81M$3.10B$5.62B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-3.3020.4930.2925.74Price / Sales3.76356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book1.108.608.826.15Net Income-$42.26M-$54.65M$3.25B$265.06M7 Day Performance12.21%5.86%3.71%2.60%1 Month Performance92.57%8.86%5.85%2.83%1 Year Performance-60.95%13.33%29.92%25.58% Contineum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTNMContineum Therapeutics3.4891 of 5 stars$7.26+4.5%$22.50+209.9%-58.0%$179.81M$50M-3.3031Short Interest ↓SIGASiga Technologies2.0701 of 5 stars$9.21-2.9%N/A-28.3%$658.67M$138.72M8.1440GYREGyre Therapeutics0.0899 of 5 stars$6.97-1.5%N/A-17.6%$653.98M$105.76M348.9240News CoverageEarnings ReportMRVIMaravai LifeSciences3.705 of 5 stars$2.55+23.6%$5.75+125.8%-68.4%$648.36M$259.18M-2.23610Analyst ForecastGap UpABUSArbutus Biopharma2.5694 of 5 stars$3.38+0.7%$5.50+63.0%-8.4%$646.99M$6.17M-11.6490Analyst ForecastAnalyst RevisionZVRAZevra Therapeutics2.4517 of 5 stars$11.69-0.1%$23.71+102.9%+27.3%$639.48M$23.61M-6.1620News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionPROKProKidney3.3998 of 5 stars$2.18-3.8%$6.25+187.4%+6.1%$636.62M$80K-3.623News CoverageEarnings ReportShort Interest ↓Gap DownDNTHDianthus Therapeutics1.1871 of 5 stars$19.73+4.4%$53.00+168.6%-28.9%$636.45M$6.24M-6.0980News CoverageEarnings ReportAnalyst RevisionMGTXMeiraGTx4.5799 of 5 stars$7.83-0.2%$24.00+206.7%+108.3%$630.42M$33.28M-3.38300News CoverageEarnings ReportGHRSGH Research3.038 of 5 stars$12.10+2.5%$32.00+164.5%+29.8%$629.67MN/A-16.3510News CoveragePositive NewsEarnings ReportAnalyst RevisionDAWNDay One Biopharmaceuticals2.7684 of 5 stars$6.10+3.3%$25.33+315.6%-53.4%$625.34M$131.16M-6.4360 Related Companies and Tools Related Companies SIGA Competitors GYRE Competitors MRVI Competitors ABUS Competitors ZVRA Competitors PROK Competitors DNTH Competitors MGTX Competitors GHRS Competitors DAWN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTNM) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access